Loading...
Indian Pharmaceutical Exporter · #11 for Rituximab · $86.7K export value · DGFT Verified
PNT Pharma is the #11 Indian exporter of Rituximab with $86.7K in export value and 12 verified shipments. PNT Pharma holds a 0.5% market share in Rituximab exports across 1 countries. The company exports 2 pharmaceutical products worth $389.8K across 1 therapeutic categories.
| COLOMBIA | $600.0K | 12 | 8.7% |
| VENEZUELA | $500.0K | 10 | 7.2% |
| PHILIPPINES | $383.0K | 12 | 5.5% |
| PERU | $371.3K | 17 | 5.4% |
| UNITED STATES | $350.9K | 25 | 5.1% |
| BANGLADESH | $271.1K | 6 | 3.9% |
India exports Rituximab to 104 countries. The top destination is SRI LANKA (21.7%), followed by MEXICO and KENYA.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| JSC R-PHARM | RUSSIA | $550.0K | 11 |
| ABC PHARMA SERVICES (PVT) LTD | SRI LANKA | $430.6K | 10 |
| DR.REDDYS LABORATORIES PHILIPPINES | PHILIPPINES | $368.9K | 8 |
| STATE PHARMACEUTICALS CORPORATION | SRI LANKA | $300.0K | 6 |
| LABORATORIOS LEGRAND S A | COLOMBIA | $250.0K | 5 |
| LABORATORIOS LEGRAND S.A | COLOMBIA | $250.0K | 5 |
| STATE PHARMACEUTICALS CORPORATION O | SRI LANKA | $150.0K | 3 |
| XXAROXXPHAXXA SXX DXXC V | MEXICO | $100.0K | 2 |
| DROGUERIA MK LAB S.A.C | PERU | $100.0K | 2 |
| SYNTEGON TECHNOLOGY GMBH | GERMANY | $100.0K | 2 |
India's Rituximab is purchased by 292 buyers worldwide. The top buyer is JSC R-PHARM (RUSSIA), followed by ABC PHARMA SERVICES (PVT) LTD and DR.REDDYS LABORATORIES PHILIPPINES.
India exported $9.4M worth of Rituximab through 1,215 shipments from 164 suppliers to 104 countries, serving 292 buyers globally. PNT Pharma contributes $86.7K to this total, accounting for 0.5% of India's Rituximab exports.
PNT Pharma's average Rituximab shipment value is $7.2K per consignment, based on 12 shipments totaling $86.7K.
PNT Pharma ranks #11 among 164 Indian Rituximab exporters with a 0.5% market share. The top 3 exporters are RELIANCE LIFE SCIENCES PRIVATE LIMITED ($4.1M), DR.REDDY'S LABORATORIES LTD ($3.2M), DR REDDYS LABORATORIES LIMITED ($550.0K). PNT Pharma processed 12 shipments to 1 destination countries.
What PNT Pharma must comply with to export Rituximab to its top destination countries
Approval Process
Generic registration under Mexican health law. NOM standards apply.
Timeline: 12–18 months
GMP & Export Requirements
Mexican GMP (NOM-059-SSA1); COFEPRIS overseas inspection or PIC/S certificate
Sanitary Import Permit from COFEPRIS; import licence via SAT
Note: COFEPRIS participates in PIC/S, easing recognition of PIC/S certificates from Indian authorities.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #11 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 9 | R.S. SURGIPHARM PRIVATE LIMITED | $118.2K | 63 | 2 | $1.9K |
| 10 | RMPL PHARMA LLP | $92.7K | 55 | 9 | $1.7K |
| 11 | PNT PHARMA ★ | $86.7K | 12 | 1 | $7.2K |
| 12 | SANSKRUTI PHARMA | $71.6K | 62 | 3 | $1.2K |
| 13 | HEET HEALTHCARE PRIVATE LIMITED | $58.3K | 10 | 3 | $5.8K |
PNT Pharma ranks #11 among 164 Indian Rituximab exporters. Average shipment value of $7.2K compared to the market average of $57.4K. The closest competitors by value are R.S. SURGIPHARM PRIVATE LIMITED and RMPL PHARMA LLP.
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 389 | 32.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 325 | 26.7% |
| Bombay Air | 85 | 7.0% |
| Bombay Air Cargo | 58 | 4.8% |
| HYDERABAD ACC (INHYD4) | 46 | 3.8% |
| DELHI AIR CARGO ACC (INDEL4) | 45 | 3.7% |
| DELHI AIR | 35 | 2.9% |
| AHEMDABAD AIR | 26 | 2.1% |
PNT Pharma also exports these advanced oncology products. Each links to the detailed product page.
PNT Pharma exports 2 products worth $389.8K. Beyond Rituximab, top products include Trastuzumab. View the complete PNT Pharma profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Rituximab — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify manufacturer licensing and export certifications with the official agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 104+ countries, 292+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level details, pricing data, buyer connections, and competitive analysis for PNT Pharma's Rituximab exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
PNT Pharma
Full Company Profile →
2 products · $389.8K total trade · 1 categories
Access shipment-level records, pricing trends, and buyer contacts for PNT Pharma.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Rituximab. For current shipment-level data, contact TransData Nexus.